作者
Muttiah Barathan, Ahmad Khusairy Zulpa, Kumutha Malar Vellasamy, Vanitha Mariappan, Naveen Kumar Hawala Shivashekaregowda, Zaridatul Aini Ibrahim, Jamuna Vadivelu
发表日期
2021/9/1
期刊
in vivo
卷号
35
期号
5
页码范围
2675-2685
出版商
International Institute of Anticancer Research
简介
Background/Aim
Isoniazid is an antibiotic used for the treatment of tuberculosis. Previously, we found that the isoniazid derivative (E)-N’-(2,3,4-trihydroxybenzylidene) isonicotinohydrazide (ITHB4) could be developed as novel antimycobacterial agent by lead optimization. We further explored the ability of this compound compared to zerumbone in inhibiting the growth of MCF-7 breast cancer cells.
Materials and Methods
Cytotoxicity was measured by the MTT assay and further confirmed via apoptosis, ROS, cell cycle, DNA fragmentation and cytokine assays.
Results
ITHB4 demonstrated a lower IC50 compared to zerumbone in inhibiting the proliferation of MCF-7 cells. ITHB4 showed no toxicity against normal breast and human immune cells. Apoptosis assay revealed that ITHB4, at a concentration equal to the IC50, induces apoptosis of MCF-7 cells and cell cycle arrest at the sub-G1 and G2/M phases. ITHB4 …
引用总数
学术搜索中的文章